EW Q2 2022 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$50B

Q2 2022 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.4B-0.2% YoY

Gross Profit

$1.1B79.2% margin

Operating Income

$428M31.2% margin

Net Income

$406M29.6% margin

EPS (Diluted)

$0.65

QoQ Revenue Growth

+2.4%

Cash Flow

Operating Cash Flow

$332M

Free Cash Flow

$289M

Stock-Based Comp.

$36M

Balance Sheet

Total Assets

$8.4B

Total Liabilities

$2.5B

Stockholders' Equity

$5.9B

Cash & Equivalents

$1.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.4B	$1.4B	-0.2%
Gross Profit	$1.1B	$1.1B	+3.6%
Operating Income	$428M	$451M	-4.9%
Net Income	$406M	$490M	-17.0%

Revenue Segments

Transcatheter Heart Valves

$907M66%

Surgical Heart Valve Therapy

$229M17%

Critical Care

$211M15%

Transcatheter Mitral And Tricuspid Therapies

$28M2%

Geographic Segments

UNITED STATES

$801M58%

Europe

$303M22%

Rest of World

$147M11%

JAPAN

$123M9%